EMERYVILLE, Calif., May 09, 2018 (GLOBE NEWSWIRE) -- Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, will be presenting its portfolio of commercialized products at Techonomy New York this morning. Amyris has enjoyed the benefit of successfully commercializing more than 10 products since 2012 that have all achieved strong commercial success and will be presenting this track record and its technology platform at this event.
Amyris’s combination of No Compromise™ product sales and a value share/royalty business model is delivering strong gross margin performance. Amyris expects to generate more value share/royalty payments than partner collaboration payments this year, and is on track for another record year of profitable growth as measured by strong gross margin performance on sales revenue.
“Both our Biossance consumer business and No Compromise™ ingredients business performed very well in the first quarter,” said John Melo, Amyris President and CEO. In January of 2017, our Biossance business was growing by about 198 consumer purchasers a day, and, by April 2018, this grew by about 1,240 consumers a day and we are tracking to end the year at around 4,000 new consumers a day buying a Biossance product.
Continued Melo, “We have introduced one of the fastest growing clean beauty brands in the U.S., plus we are very fortunate to have strong traction with commercial products that have become the leading ingredients in our customers’ portfolios. We have a business model that is just starting to reflect our No Compromise™ best-in-class technology platform. We welcome everyone who is unfamiliar with our product portfolio and the level of disruption we are achieving to join the videocast of our BioDisrupt 2018 conference on May 22 to discover how we are meeting consumer needs and making some of the best performing ingredients for our partners.”
About Amyris
Amyris is the integrated renewable products company that is enabling the world’s leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules and produce specialty ingredients and consumer products. The company is delivering its No Compromise™ products and services across a number of markets, including specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, pharmaceuticals, and nutraceuticals. More information about the company is available at www.amyris.com.
Forward-Looking Statements
This release contains forward-looking statements, and any statements other than statements of historical fact could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events (such as expected gross margin performance and business growth, anticipated value share/royalty payments relative to partner collaboration payments, and expected numbers of new Biossance consumers), that involve risks and uncertainties. These statements are based on management's current expectations and actual results and future events may differ materially due to risks and uncertainties, including risks related to Amyris's liquidity and ability to fund operating and capital expenses, potential delays or failures in development, production and commercialization of products, risks related to Amyris's reliance on third parties, and other risks detailed from time to time in filings Amyris makes with the Securities and Exchange Commission, including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Amyris disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.
Amyris, the Amyris logo, Biossance, and No Compromise are trademarks or registered trademarks of Amyris, Inc. in the U.S. and/or other countries. All other trademarks are the property of their respective owners.
Contact:
Peter DeNardo
Director, Investor Relations and Corporate Communications
Amyris, Inc.
+1 (510) 740-7481
investor@amyris.com
pr@amyris.com